S-Alpha Therapeutics
PrivateLast Round
Series C
Nov 5, 2025
Total Funding Raised
$19.9M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
S-Alpha Therapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series C round in November 2025.
S-Alpha Therapeutics is a digital therapeutics company that develops evidence-based software-as-a-medical-device products for ophthalmology, neuropsychiatry, cancer, and immunology.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Patient Engagement, Telemedicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
S-Alpha Therapeutics Comparables
Compare S-Alpha Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NovaSight | 82% | |
| WELT Corp. | 81% | |
| Nunaps | 80% |
For institutional investors. Book with your work email.
S-Alpha Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 5, 2025 | ||||
| Strategic | Mar 28, 2024 | ||||
| Series B | Mar 15, 2023 | ||||
| Series A | Jul 31, 2021 | ||||
| Seed | Nov 20, 2020 |
For institutional investors. Book with your work email.
S-Alpha Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hana Ventures | Series A, Series B, Seed |
| LigaChem Biosciences | Seed |
| KDB Capital Corp | Series B |
| Korea Investment Partners | Series A, Series B |
| Stonebridge Ventures | Series A, Series B |
| CJ Investment | Series A, Series B |
| Mirae Asset Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2025
Raised Series C round
- Aug 27, 2024
Grew 19% QoQ, from 16 to 19 employees.
For institutional investors. Book with your work email.
S-Alpha Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about S-Alpha Therapeutics's valuation, stock price, and market status.
Is S-Alpha Therapeutics a public or private company?
S-Alpha Therapeutics is a private company.
What is the current stock price of S-Alpha Therapeutics?
S-Alpha Therapeutics is a private company, so its shares have no public market price. Caplight tracks S-Alpha Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is S-Alpha Therapeutics worth (valuation)?
Valuation information for S-Alpha Therapeutics is not publicly available.
Can I buy S-Alpha Therapeutics stock?
S-Alpha Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was S-Alpha Therapeutics's last funding round?
S-Alpha Therapeutics's most recent funding round was Series C on November 5, 2025.
Who are the main investors in S-Alpha Therapeutics?
Key investors in S-Alpha Therapeutics include Hana Ventures, STIC Ventures.
Will S-Alpha Therapeutics IPO soon?
No public IPO plans have been announced for S-Alpha Therapeutics.
How can I track S-Alpha Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in S-Alpha Therapeutics's shares on secondary markets.